Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents of ENZON PHARMACEUTICALS, INC. from 31 Dec 2017 to 31 Dec 2025

Taxonomy & unit: us-gaap: USD
Description: Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
Summary: ENZON PHARMACEUTICALS, INC. quarterly Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents in USD history and change rate from 31 Dec 2017 to 31 Dec 2025.
ENZON PHARMACEUTICALS, INC. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents for the quarter ending 31 Dec 2025 was $42,574,000, a 9.1% decline year-over-year.
Source SEC data: View on sec.gov

Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Quarterly (USD)

Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, YoY Quarterly Change (%)

ENZON PHARMACEUTICALS, INC. Quarterly Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents (USD)

Period	Value	YoY Chg	Change %	Date	Report	Filed	Fiscal Year	Fiscal Period
Q4 2025	$42,574,000	-$4,285,000	-9.1%	31 Dec 2025	10-K	02 Mar 2026	2025	FY
Q3 2025	$43,256,000	-$3,377,000	-7.2%	30 Sep 2025	10-Q	12 Nov 2025	2025	Q3
Q2 2025	$44,294,000	-$1,935,000	-4.2%	30 Jun 2025	10-Q	14 Aug 2025	2025	Q2
Q1 2025	$44,966,000	-$1,022,000	-2.2%	31 Mar 2025	10-Q	09 May 2025	2025	Q1
Q4 2024	$46,859,000	-$153,000	-0.32%	31 Dec 2024	10-K	02 Mar 2026	2025	FY
Q3 2024	$46,633,000	+$76,000	+0.16%	30 Sep 2024	10-Q	12 Nov 2025	2025	Q3
Q2 2024	$46,229,000	+$98,000	+0.21%	30 Jun 2024	10-Q	14 Aug 2025	2025	Q2
Q1 2024	$45,988,000	+$111,000	+0.24%	31 Mar 2024	10-Q	09 May 2025	2025	Q1
Q4 2023	$47,012,000	+$30,000	+0.06%	31 Dec 2023	10-K	02 Mar 2026	2025	FY
Q3 2023	$46,557,000	-$295,000	-0.63%	30 Sep 2023	10-Q	05 Nov 2024	2024	Q3
Q2 2023	$46,131,000	-$663,000	-1.4%	30 Jun 2023	10-Q	08 Aug 2024	2024	Q2
Q1 2023	$45,877,000	-$1,552,000	-3.3%	31 Mar 2023	10-Q	10 May 2024	2024	Q1
Q4 2022	$46,982,000	-$659,000	-1.4%	31 Dec 2022	10-K	21 Feb 2025	2024	FY
Q3 2022	$46,852,000	-$1,039,000	-2.2%	30 Sep 2022	10-Q	09 Nov 2023	2023	Q3
Q2 2022	$46,794,000	-$1,397,000	-2.9%	30 Jun 2022	10-Q	07 Aug 2023	2023	Q2
Q1 2022	$47,429,000	-$758,000	-1.6%	31 Mar 2022	10-Q	05 May 2023	2023	Q1
Q4 2021	$47,641,000	-$501,000	-1%	31 Dec 2021	10-K	20 Mar 2024	2023	FY
Q3 2021	$47,891,000	-$296,000	-0.61%	30 Sep 2021	10-Q	09 Nov 2022	2022	Q3
Q2 2021	$48,191,000	+$42,282,000	+716%	30 Jun 2021	10-Q	04 Aug 2022	2022	Q2
Q1 2021	$48,187,000	+$43,043,000	+837%	31 Mar 2021	10-Q	04 May 2021	2021	Q1
Q4 2020	$48,142,000	$0	0%	31 Dec 2020	10-K	16 Feb 2023	2022	FY
Q3 2020	$48,187,000	+$38,171,000	+381%	30 Sep 2020	10-Q	26 Apr 2022	2022	Q1
Q2 2020	$5,909,000	+$2,542,000	+75%	30 Jun 2020	10-Q	05 Aug 2021	2021	Q2
Q1 2020	$5,144,000	+$1,586,000	+45%	31 Mar 2020	10-Q	04 May 2021	2021	Q1
Q4 2019	$48,142,000	+$41,642,000	+641%	31 Dec 2019	10-Q	26 Apr 2022	2022	Q1
Q3 2019	$10,016,000	+$3,290,000	+49%	30 Sep 2019	10-Q	09 Nov 2020	2020	Q3
Q2 2019	$3,367,000	-$3,599,000	-52%	30 Jun 2019	10-Q	29 Jul 2020	2020	Q2
Q1 2019	$3,558,000			31 Mar 2019	10-Q	30 Apr 2020	2020	Q1
Q4 2018	$6,500,000	-$978,000	-13%	31 Dec 2018	10-K	23 Feb 2021	2020	FY
Q3 2018	$6,726,000			30 Sep 2018	10-Q	06 Nov 2019	2019	Q3
Q2 2018	$6,966,000			30 Jun 2018	10-Q	07 Aug 2019	2019	Q2
Q4 2017	$7,478,000			31 Dec 2017	10-K	19 Feb 2020	2019	FY

* An asterisk sign (*) next to the value indicates that the value is likely invalid.